Paul Hodgkins, MSC, PhD

Shire Pharmaceuticals, Inc.
Health Economics
725 Chesterbrook Boulevard
Wayne, PA
USA 19087

Papers:
2.3 Satisfying Effectiveness Requirements for Novel ADHD Pharmacotherapies: Functional Impairment and Health-Related Quality of Life Outcome Measures in International Trials 3.3 Preferences for Non-Stimulant ADHD Treatment Characteristics Among Children/Adolescents with ADHD and Their Caregivers 3.7 Economic Burden of ADHD 3.36 Exploring Adolescents' Perspective of Functioning in ADHD for Evaluating Treatment Outcomes

Copyright ©2013 - American Academy of Child Adolescent Psychiatry. All Rights Reserved.